Brought to you by 
The Medicines Co. to buy Ionsys developer Incline Therapeutics for $185mm
14 Dec 2012
Executive Summary
On the same day it gained rights to BMS’s active hemostat Recothrom, critical care-focused The Medicines Co. (TMC) is adding yet another product to its portfolio, through the acquisition of privately held Incline Therapeutics Inc. for $185mm in cash up front plus up to $205mm in earn-outs tied to the following: signing a Japanese licensing agreement for Incline’s acute postoperative pain candidate Ionsys; and achieving regulatory approvals and sales milestones.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Transdermal
-
Drug Delivery
-
Medical Devices
- Infusion Therapy Equipment and Supplies
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Includes Earnout
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
The Medicines Co. to buy Ionsys developer Incline Therapeutics for $185mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice